[Ip-health] IGFAM - Differential Pricing Discussion Paper

Charles Clift charlesclift at tiscali.co.uk
Fri Nov 19 02:03:03 PST 2010

DFID has now extended the deadline for completing this survey to 5 December.
More views on this topic would be gratefully received.


IGFAM is the UK Industry Government Forum on Access to Medicines established
to promote dialogue on how industry and government can work together to
promote access to medicines in developing countries. More details on IGFAM
are provided at http://www.dfid.gov.uk/Global-Issues/Emerging-policy/IGFAM  

DFID, on behalf of IGFAM, commissioned Professor Prashant Yadav of
MIT-Zaragoza to review current knowledge about differential pricing, its
current prevalence and to suggest ways in which it might be encouraged in
such a way as to enhance access to medicines in low and middle income
developing countries. 

IGFAM is interested to solicit the views of stakeholders and other
interested parties on Professor Yadav's paper as a means of stimulating
debate on the issue of differential pricing, and on policies which
governments, donor organisations and industry could adopt to facilitate
access to medicines to poor patients in developing countries. The full paper
and a summary are available at

We would therefore be very grateful if you could take a little time (less
than fifteen minutes) to complete the
<http://www.surveymonkey.com/s/W7XZBMF> survey at

Please feel free to add your own comments and suggestions in the space
provided in the survey. 

The deadline for completing the survey is now 5 December. 

We will then publish a report based on the responses by the end of December.

Best wishes

Saul Walker (DFID)

Jon Pender (GSK)

Co-chairs of IGFAM




Saul Walker

Senior Policy Advisor, Access to Medicines

Health Services Team

Department for International Development

Tel:   +44 20 7023 1122

Mob: +44 7748 920 597

Fax:  +44 20 7023 0428




DFID, the Department for International Development: leading the UK
Government's fight against world poverty. Find out more at

More information about the Ip-health mailing list